Bio-Rad Laboratories (NYSE: BIO) reported earnings on May 1. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended March 31 (Q1), Bio-Rad Laboratories met expectations on revenues and beat expectations on earnings per share.

Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share contracted.

Gross margins grew, operating margins dropped, net margins dropped.

Revenue details
Bio-Rad Laboratories tallied revenue of $486.3 million. The three analysts polled by S&P Capital IQ hoped for revenue of $492.4 million on the same basis. GAAP reported sales were 0.2% higher than the prior-year quarter's $485.1 million.

My

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
EPS came in at $1.09. The three earnings estimates compiled by S&P Capital IQ averaged $1.02 per share. GAAP EPS of $1.09 for Q1 were 6.0% lower than the prior-year quarter's $1.16 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Margin details
For the quarter, gross margin was 57.3%, 10 basis points better than the prior-year quarter. Operating margin was 11.2%, 260 basis points worse than the prior-year quarter. Net margin was 6.4%, 40 basis points worse than the prior-year quarter.

Looking ahead
Next quarter's average estimate for revenue is $522.3 million. On the bottom line, the average EPS estimate is $1.16.

Next year's average estimate for revenue is $2.15 billion. The average EPS estimate is $5.36.

Investor sentiment
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 182 members out of 191 rating the stock outperform, and nine members rating it underperform. Among 51 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 51 give Bio-Rad Laboratories a green thumbs-up, and none give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Bio-Rad Laboratories is outperform, with an average price target of $111.50.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.